受体型酪氨酸激酶变异体对结肠癌细胞侵袭能力影响的研究

目的研究受体型酪氨酸激酶变异体RON△160表达对结肠癌细胞迁移、浸润能力的影响.方法将携有受体型酪氨酸激酶RON变异体RON△160 cDNA的质粒转染入结肠癌细胞株RKO细胞,挑选稳定转染克隆,以过河实验和Transwel 趋化运动实验检测细胞迁移能力;Matrigel基质浸润实验检测细胞浸润能力,Western blot检测E-钙粘连蛋白(E-cadherin)表达的变化.结果转染RON△160后RKO细胞的过河时间为(38.00±1.63)h,明显短于未转染组与载体对照组的(69.50±2.52)h与(72.00±1.63)h,差异均有统计学意义(均P<0.05).转染后RKO细胞的穿膜能力显著增强,穿膜细胞数为(59.22±6.67)个/HP、未转染组为(25.90±4.56)个/HP、载体对照组为(28.33±6.75)个/HP,差异均有统计学意义(均P<0.05).转染RON△160后,RKO细胞中E-cadherin表达降低(P<0.05).结论 RON△160转染可以降低E-cadherin表达,降低肿瘤细胞间的黏附性,增加结肠癌细胞RKO的移动、浸润能力.RON△160的表达可能是结肠癌浸润、转移的机制之一.     

miRNAs在甲状腺乳头状癌中的表达及临床病理意义

目的：探讨甲状腺乳头状癌（PTC）中特征性的miRNA表达谱以及临床病理意义。方法对52例PTC及7例良性甲状腺肿瘤手术切除标本采用基因芯片技术及RNA印迹杂交法检测miRNA的表达,对过表达的miRNA表达水平与PTC临床病理特征之间的关系进行分析。结果（1）用基因芯片技术筛检发现 PTC 组织中5例过表达的 miRNAs（miR-375、miR-34a、miR-146b、miR-222、miR-31）。（2）RNA印迹杂交法验证芯片结果及检测其他miRNAs结果显示：miR-34a、miR-146b、miR-31、miR-21和miR-221在PTC组织中的表达水平较癌旁正常甲状腺组织显著升高（P＜0.05）。MiR-146b和miR-221在PTC组织中的过表达率较良性甲状腺肿瘤组织显著升高（P＜0.01）。PTC患者中包膜侵犯组、淋巴结转移组、TNM分期III- IV期组及AGES系统评分≥5分组miR-221的表达水平均明显高于相应对照组（P＜0.05或0.01）;而男性PTC患者的miR-146b表达水平明显高于女性PTC患者（P＜0.05）。结论 miR-146b、miR-221、miR-21和miR-31的过表达与PTC的发生、发展有关;过表达的miR-221和miR-146b与PTC的预后不良有关。     

Uptake of Well‐Defined,Highly Glycosylated,Pentafluorostyrene‐Based Polymers and Nanoparticles by Human Hepatocellular Carcinoma Cells

Chain length, size, composition, surface charge, and other properties of polymeric materials affect their recognition and uptake by cells and must be optimized to deliver polymers selectively to their target. However, it is often not possible to precisely modify selected properties without changing other parameters. To overcome these difficulties, well‐defined poly(pentafluorostyrene)‐based polymers are prepared that can be grafted via thiol/para‐fluorine “click” reaction with 1‐thio‐β‐D ‐glucose and 1‐thio‐β‐D ‐galactose. Fluorescence microscopy and flow cytometry show that nanoparticles are taken up by HepG2 cells to a higher degree than the respective water‐soluble polymers, and that internalization of both galactosylated homo‐ and nanoprecipitated block copolymers is enhanced.

     

Anti-HepG-2 Cell Properties of Rare Earth Tungstosilicic Polyoxometalates Containing 5-Fluorouracil

Two novel rare earth tungstosilicic polyoxometalate containing 5-fluorouracil,K26(C4H4FN2O2)8Pr(SiW11O39)4·10H2O(FPSW) and K26(C4H4FN2O2)8Sm(SiW11O39)4·9H2O(FSSW),were synthesized and their structure were characterized by using elemental analysis,FTIR spectra,X-ray powder diffraction and TG.The antitumor activity tests of the compounds FPSW and FSSW were carried out by the methyl thiazolyl tetrazolium method in hepatocellular carcinoma cell HepG-2.The results showed that FPSW and FSSW could inhibit the HepG-2 cells in vitro significantly.The EC50 of FPSW and FSSW is 1.94×10-5 and 1.32×10-5 mol·L-1 respectively.The therapeutic index of FPSW and FSSW is 0.76 and 1.58 respectively.     

Interventional Radionuclide Therapy of Hepatocellular Carcinoma:Assessment of Intratumoral Retention of HPMA Copolymers

To develop new radiopharmaceuticals for the interventional radionuclide therapy of recurrent hepatocellular carcinoma, poly(HPMA)-APMA-DTPA[HPMA=N-(2-hydroxypropyl) methacrylamide; APMA=N-(3-aminopro-pyl)methacrylamide; DTPA=diethylenetriaminepentaacetic acid] was synthesized by free radical precipitation polymerization in acetone/dimethylsulfoxide with N,N′-azobis(isobutyronitrile) as the initiator. The copolymers were characterized with nuclear magnetic resonance(NMR) spectroscopy and gel permeation chromatography(GPC, M_n=2.2×10⁴, M_w/M_n=1.38). Subsequently, poly(HPMA)-APMA-DTPA was conjugated with ^99mTc radionuclide. Prolonged retention of poly(HPMA)-APMA-DTPA conjugate within the tumor tissues was demonstrated by single-photon emission computed tomography computed tomography(SPECT-CT) at 1, 2, 4 and 24 h following intra-tumoral injection of the conjugate to hepatocellular carcinoma xenografts in mice. DTPA-^99mTc was also synthesized and characterized for comparison. The data suggest that the poly(HPMA)-APMA-DTPA conjugates might be useful for the interventional radionuclide therapy of recurrent hepatocellular carcinoma in humans.     

Prediction of early response to radiotherapy of uterine carcinoma with dynamic contrast-enhanced MR imaging using pixel analysis of MR perfusion imaging

Purpose

To assess the predictability of the response to radiotherapy of uterine carcinoma, this study retrospectively analyzed dynamic contrast-enhanced magnetic resonance images (DCE-MRI) taken before radiotherapy.

Materials and Methods

Forty-two patients with uterine carcinoma were studied, of whom 22 had adenocarcinoma and 20 had squamous cell carcinoma (SCC). In DCE-MRI analysis, two parameters, SIe and R_down, were measured. SIe is a median value for the degree of signal intensity change in all selected pixels in the tumor at 1–2 min after contrast agent injection. R_down is the ratio of the number of down-sloped pixels to that of all selected pixels 3–7 min after injection. The tumor volume reduction rate (TVRR) was measured by MRI-based volumetry in pre- and post-radiotherapy transverse T2-weighted images.

Results

Overall, TVRR was significantly correlated to both SIe (r=0.37, P=.015) and R_down (r=0.73, P<.0001). In the separate patient groups, SIe but not R_down was significantly different between the adenocarcinoma and SCC patients (t=3.64, P<.001). TVRR was not correlated to SIe in any group. TVRR was significantly correlated to R_down in adenocarcinoma patients (r=0.78, P<.001) but not in SCC patients.

Conclusion

SIe may reflect differences in histological characteristics. R_down may be useful for predicting the response to radiotherapy of uterine carcinoma.     

Analysis of Significance of Unite Examination of AFP and DNA Polymorphism of P3 Promoter of IGF-ⅡGene

The DNA of P3 promoter region of IGF-Ⅱ gene was obtained by means of PCR technique. The examination of DNA polymorphism by restriction endonuclease BstE Ⅱ and the examination of AFP by bioluminescence immunoassay technique were carried out. The results have a significant difference(P<0.005). But the positive rate of AFP is higher than that of DNA polymorphism. The experimental result shows that the change of the DNA polymorphism of IGF-Ⅱis not the only carcinogenic factor. The suggested unite examination is the best method for the diagnosis of the primary hepatocellular carcinoma.     

CoMFA and CoMSIA studies on a new series of xanthone derivatives against the oral human epidermoid carcinoma (KB) cancer cell line

Abstract  A new series of xanthone derivatives against the oral human epidermoid carcinoma (KB) cancer cell line is examined to determine the relationship between the structural properties and the biological activity of these compounds—the 3-D quantitative structure–activity relationship (3D-QSAR)—using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). The best CoMFA and CoMSIA models were obtained using the atom-based alignment of 33 compounds, 22 training compounds and 11 tested compounds, and these give desirable statistics; those for the CoMFA standard model were: r _cv² = 0.691, r ² = 0.998, S _press = 0.178, s = 0.014 and F = 1080.765, while CoMSIA combined steric, electrostatic, hydrophobic and hydrogen-bond acceptor fields: r _cv² = 0.600, r ² = 0.988, S _press = 0.206, s = 0.034 and F = 284.433. The 3D-QSAR models calculated satisfactory test set activities. The 3D-QSAR contour plots correlated strongly with the experimental data for the binding topology. For this reason, these results would be beneficial for predicting affinities with the compounds of interest, and they are advantageous for guiding the design and synthesis of new and more effective anticancer agents. Graphical abstract   A new and more effective anticancer agent of xanthone derivatives against the oral human epidermoid carcinoma (KB) cell line, as investigated by CoMFA and CoMSIA analysis     

Discovery of a Prenylated Flavonol Derivative as a Pin1 Inhibitor to Suppress Hepatocellular Carcinoma by Modulating MicroRNA Biogenesis

Peptidyl‐prolyl cis‐trans isomerase Pin1 plays a crucial role in the development of human cancers. Recently, we have disclosed that Pin1 regulates the biogenesis of miRNA, which is aberrantly expressed in HCC and promotes HCC progression, indicating the therapeutic role of Pin1 in HCC therapy. Here, 7‐(benzyloxy)‐3,5‐dihydroxy‐2‐(4‐methoxyphenyl)‐8‐(3‐methylbut‐2‐en‐1‐yl)‐4H‐chromen‐4‐one ( AF‐39 ) was identified as a novel Pin1 inhibitor. Biochemical tests indicate that AF‐39 potently inhibits Pin1 activity with an IC₅₀ values of 1.008 μm , and also displays high selectivity for Pin1 among peptidyl prolyl isomerases. Furthermore, AF‐39 significantly suppresses cell proliferation of HCC cells in a dose‐ and time‐dependent manner. Mechanistically, AF‐39 regulates the subcellular distribution of XPO5 and increases miRNAs biogenesis in HCC cells. This work provides a promising lead compound for HCC treatment, highlighting the therapeutic potential of miRNA‐based therapy against human cancer.